Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-02-16 Sale | 2024-02-16 9:48 pm | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 3,939 | $1.08 | $4,254 | 689,732 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:42 pm | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 11,549 | $1.08 | $12,473 | 1,795,401 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:31 pm | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 4,170 | $1.08 | $4,504 | 603,841 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:29 pm | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 3,374 | $1.08 | $3,644 | 554,235 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:21 pm | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 4,400 | $1.08 | $4,752 | 589,893 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:15 pm | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 5,010 | $1.08 | $5,411 | 616,136 (Direct) | View |
| 2024-02-16 Sale | 2024-02-16 9:13 pm | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 3,939 | $1.08 | $4,254 | 751,597 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:43 pm | Seres Therapeutics Inc. | MCRB | Cloghessy Paula See Remarks | 2,904 | $1.35 | $3,920 | 73,936 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:40 pm | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 8,552 | $1.35 | $11,545 | 199,132 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:40 pm | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 2,907 | $1.35 | $3,924 | 42,535 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:39 pm | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 4,066 | $1.35 | $5,489 | 215,383 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:39 pm | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 4,156 | $1.35 | $5,611 | 154,392 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:39 pm | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 4,066 | $1.35 | $5,489 | 101,072 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:36 pm | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 4,232 | $1.35 | $5,713 | 50,746 (Direct) | View |
| 2023-10-30 Sale | 2023-10-31 9:36 pm | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 3,886 | $1.35 | $5,246 | 94,223 (Direct) | View |
| 2023-04-28 Sale | 2023-05-01 4:46 pm | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 7,038 | $5.19 | $36,527 | 59,696 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Graves Kurt Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Kender Richard N Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Biondi Paul Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Fraser Claire Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Dere Willard H Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Ausiello Dennis A Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-04-04 Option Award | 2024-04-08 4:45 pm | N/A 2034-04-03 | Seres Therapeutics Inc. | MCRB | Berenson Stephen Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2024-03-25 Option Award | 2024-03-27 4:20 pm | N/A 2034-03-24 | Seres Therapeutics Inc. | MCRB | Thorell Marella See Remarks | 700,000 | $0 | 700,000 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:48 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 10,625 | $0 | 689,732 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:48 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 537,280 | $0 | 689,732 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:42 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 31,250 | $0 | 1,795,401 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:42 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 1,566,330 | $0 | 1,795,401 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:31 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 11,250 | $0 | 603,841 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:31 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 506,655 | $0 | 603,841 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:29 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 10,625 | $0 | 554,235 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:29 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 506,655 | $0 | 554,235 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:21 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 11,875 | $0 | 589,893 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:21 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 537,280 | $0 | 589,893 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:15 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 11,875 | $0 | 616,136 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:15 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 506,655 | $0 | 616,136 (Direct) | View |
| 2024-02-15 Exercise | 2024-02-16 9:13 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 10,625 | $0 | 751,597 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 9:13 pm | N/A 2034-02-13 | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 537,280 | $0 | 751,597 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:43 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Cloghessy Paula See Remarks | 9,418 | $0 | 73,936 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:43 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Cloghessy Paula See Remarks | 18,835 | $0 | 73,936 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:40 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 27,838 | $0 | 199,132 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:40 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 55,675 | $0 | 199,132 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:40 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 11,361 | $0 | 42,535 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:40 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Young Teresa L. See Remarks | 22,721 | $0 | 42,535 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 13,209 | $0 | 215,383 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 26,418 | $0 | 215,383 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 13,501 | $0 | 154,392 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 27,001 | $0 | 154,392 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 11,361 | $0 | 101,072 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:39 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 22,721 | $0 | 101,072 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:36 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 13,745 | $0 | 50,746 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:36 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 27,489 | $0 | 50,746 (Direct) | View |
| 2023-10-27 Exercise | 2023-10-31 9:36 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 12,623 | $0 | 94,223 (Direct) | View |
| 2023-04-27 Option Award | 2023-10-31 9:36 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 25,245 | $0 | 94,223 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:35 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Biondi Paul Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:29 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Ausiello Dennis A Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:25 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Berenson Stephen Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:25 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Fraser Claire Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:24 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Behar Gregory Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:22 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Graves Kurt Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:21 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Kender Richard N Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-23 5:21 pm | N/A 2033-06-21 | Seres Therapeutics Inc. | MCRB | Dere Willard H Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2023-04-27 Option Award | 2023-05-01 4:46 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 20,000 | $0 | 59,696 (Direct) | View |
| 2023-04-27 Option Award | 2023-05-01 4:43 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Arkowitz David Chief Financial Officer | 42,500 | $0 | 166,613 (Direct) | View |
| 2023-04-27 Option Award | 2023-05-01 4:41 pm | 2023-04-27 2027-06-18 | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 35,000 | $0 | 70,000 (Direct) | View |
| 2023-02-03 Option Award | 2023-02-07 5:50 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Ege David S. See Remarks | 142,500 | $0 | 142,500 (Direct) | View |
| 2023-02-03 Option Award | 2023-02-07 5:48 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | von Moltke Lisa See Remarks | 142,500 | $0 | 142,500 (Direct) | View |
| 2023-02-03 Option Award | 2023-02-07 5:46 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Henn Matthew R. See Remarks | 135,000 | $0 | 135,000 (Direct) | View |
| 2023-02-03 Option Award | 2023-02-07 5:45 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | DesRosier Thomas Chief Legal Officer and EVP | 127,500 | $0 | 127,500 (Direct) | View |
| 2023-02-03 Option Award | 2023-02-07 5:45 pm | N/A N/A | Seres Therapeutics Inc. | MCRB | Shaff Eric D. CEO and President | 375,000 | $0 | 375,000 (Direct) | View |